VAF347|cas:574759-62-9|西域试剂

VAF347,99.90%

产品编号：Bellancom-135750| CAS NO：574759-62-9| 分子式：C₁₇H₁₁ClF₃N₃| 分子量：349.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-135750	￥1500.00	杭州北京（现货）
Bellancom-135750	￥4500.00	杭州北京（现货）
Bellancom-135750	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

VAF347

产品介绍

VAF347 是一种细胞可渗透且高度亲和力的芳烃受体 (AhR) 激动剂，可诱导 AhR 信号传导。VAF347 抑制颗粒单核细胞 (GM 期) 前体中 CD14⁺CD11b⁺ 单核细胞的发育。VAF347 具有抗炎作用。

生物活性

VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14⁺CD11b⁺ monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory effects.

体外研究

VAF347 (0.01-20 μM; 48-72 hours; HL-60 cells) treatment enhances retinoic acid-induced cell cycle arrest.
VAF347 (20 μM; 48 hours; HL-60 cells) treatment augments retinoic acid-induced expression of AhR, Lyn, Vav1, and c-Cbl as well as p47phox. Several interactions of partners in the signalsome appear to be enhanced: Fgr interaction with c-Cbl, CD38, and with pS259c-Raf and AhR interaction with c-Cbl and Lyn.
VAF347 inhibits IL-4⁺ GM-CSF induced IL-6 production in MM1 cells with an IC₅₀ of ~5 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	HL-60 cells
Concentration:	10 nM, 100 nM, 1 μM, 10 μM, 20 μM
Incubation Time:	48 hours or 72 hours
Result:	Enhanced retinoic acid-induced cell cycle arrest in G1/0.

Western Blot Analysis

Cell Line:	HL-60 cells
Concentration:	20 μM
Incubation Time:	48 hours
Result:	Augmented retinoic acid-induced expression of AhR, Lyn, Vav1, and c-Cbl as well as p47phox.

体内研究
(In Vivo)

In wild-type mice, VAF347 treatment leads to a strong reduction of total serum IgE levels compared with vehicle-treated animals. IL-5 levels in the bronchoalveolar fluid are inhibited to a comparable degree. AhR-deficient mice are resistant to the VAF347's ability to block allergic lung inflammation in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 31.25 mg/mL (89.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8593 mL	14.2963 mL	28.5927 mL
5 mM	0.5719 mL	2.8593 mL	5.7185 mL
10 mM	0.2859 mL	1.4296 mL	2.8593 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.08 mg/mL (5.95 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.95 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.95 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.95 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。